IVF Due Date Calculator: Day 3 and Day 5 Blastocyst Transfer Due Dates with Beta hCG Dates, Trimester Calendar, and IVF Milestone Timeline

The notation “9dp5dt” means 9 days past a 5-day transfer (blastocyst), while “11dp3dt” means 11 days past a 3-day transfer (cleavage stage embryo). Both abbreviations represent the same post-fertilization timeline (14 total days from fertilization when you add embryo age to days post-transfer), but the starting point differs because a Day 5 embryo was already 5 days old at transfer while a Day 3 embryo was 3 days old. At 9dp5dt, the embryo is 14 days past fertilization total. At 11dp3dt, the embryo is also 14 days past fertilization total (11 + 3 = 14). Beta hCG is tested at this approximately 14-day post-fertilization point because that is when hCG levels from a successfully implanted embryo are reliably detectable above the threshold of standard blood tests (typically 5 mIU/mL) in the majority of pregnancies. Testing earlier than 14 days post-fertilization risks false negatives because hCG may not yet have risen to detectable levels even in successful pregnancies, while testing earlier also risks false positives if any hCG trigger shot (used in stimulated cycles) has not yet fully cleared. Clinics that administered a trigger shot during the stimulation cycle should wait at least 10 days after the trigger to ensure it is fully metabolized and cannot interfere with the beta result. The second beta test 48 hours after the first is used to confirm appropriate hCG doubling, which in a healthy early pregnancy approximately doubles every 48 to 72 hours in the early first trimester.

Beta hCG levels at the first test after IVF transfer show enormous variation between patients, and the absolute single value is far less important than the pattern of doubling between serial measurements. However, general research-based expectations for a first beta at 9dp5dt include: a level above 100 mIU/mL is generally associated with a high likelihood of a viable intrauterine pregnancy; levels between 10 and 100 mIU/mL are positive but lower and may require careful monitoring to ensure appropriate doubling; levels below 5 to 10 mIU/mL (the typical assay threshold) are negative for pregnancy. A 2014 study by Pekau and colleagues in Fertility and Sterility found that beta hCG at 9dp5dt above 50 mIU/mL predicted a higher live birth rate. That said, many pregnancies with first betas in the 15 to 50 mIU/mL range progress normally to healthy deliveries when appropriate doubling occurs. Doubling time is the critical metric: the hCG level should approximately double every 48 to 72 hours in the early first trimester (weeks 4-8), though the doubling rate may slow to every 72 to 96 hours as levels rise above 6,000 mIU/mL. Failure to double appropriately (a doubling time longer than 96 hours or a rise of less than 53% in 48 hours) may indicate a non-viable pregnancy, ectopic pregnancy, or a slow-rising pregnancy that requires close monitoring. Conversely, very high first betas (above 200 at 9dp5dt) may indicate twins and your RE clinic will typically schedule an early monitoring ultrasound around 6 to 7 weeks gestational age to evaluate for multiples. Never self-interpret beta hCG results without guidance from your reproductive endocrinologist, who will review the full context of your specific stimulation protocol, trigger shot timing, and individual hormonal background.

Most US reproductive endocrinology practices discharge IVF patients to their regular OB-GYN or midwife between 8 and 10 weeks of pregnancy (gestational age, counted from implied LMP), after confirming a visible and appropriately sized fetal heartbeat on ultrasound. The “graduation” appointment typically includes a final monitoring ultrasound (usually at 8 to 9 weeks) where the RE confirms: presence of fetal heartbeat with an appropriate heart rate (typically 150 to 170 beats per minute at 8-9 weeks); gestational sac and embryo size consistent with expected gestational age; absence of subchorionic hematoma or other structural concerns requiring RE-level monitoring; and satisfactory decline of any supplemental progesterone protocol to natural levels if the RE is planning to wean progesterone support. Many IVF clinics continue monitoring through 10 weeks before discharge if there have been complications, if the patient is carrying multiples (which require additional monitoring), or if supplemental estrogen and progesterone support are still being tapered. The transition from IVF monitoring (typically involving frequent ultrasounds and bloodwork every 1 to 2 weeks) to standard OB prenatal care (typically monthly visits in the first trimester) can feel abrupt for IVF patients who are accustomed to close surveillance, and it is common to feel anxious about the reduced monitoring frequency after discharge. This is a normal part of transitioning to a standard pregnancy course, and your OB will continue routine first trimester monitoring including the 10 to 13 week NIPT/nuchal translucency screening that is standard in US prenatal care regardless of conception method.

Frozen embryo transfer (FET) success rates in the United States are now equivalent to or higher than fresh transfer rates at most IVF clinics, a change from a decade ago when fresh transfers were generally preferred. The improvement in FET outcomes is primarily driven by advances in vitrification technology (ultra-rapid freezing that prevents ice crystal formation and cell damage), which has dramatically improved embryo survival rates after thawing from approximately 70 to 80% in the era of slow-freezing to greater than 95% survival with modern vitrification. The current US Society for Assisted Reproductive Technology (SART) national averages, available at sartcorsonline.com, show live birth rates per FET cycle of approximately 40 to 50% for patients under 35 using their own eggs, comparable to fresh transfer rates. In many clinics, FET rates now exceed fresh rates specifically because a freeze-all strategy (freezing all embryos from a stimulation cycle and transferring in a subsequent unstimulated cycle) allows the uterine environment to recover fully from the ovarian hyperstimulation and hormonal fluctuations of the fresh cycle, potentially improving endometrial receptivity. The CDC collects IVF outcome data from all US fertility clinics, and national success rate statistics by age, diagnosis, and transfer type are published annually at cdc.gov/art. Individual clinic success rates (which vary significantly based on patient population and protocol preferences) are also available through SART at sartcorsonline.com, and comparing these figures is useful when selecting or evaluating an IVF clinic.

IVF gestational age is calculated using the same 280-day convention as natural conception, but the starting point is defined differently. In a naturally conceived pregnancy, gestational age is counted from the first day of the last menstrual period (LMP), which typically precedes ovulation and fertilization by approximately 14 days. In IVF, the egg retrieval day is equivalent to the fertilization day (Day 0), and the implied LMP is defined as 14 days before the retrieval date, even though no actual menstrual period occurred at that time and the patient was undergoing ovarian stimulation. This 14-day offset means that an IVF patient is “gestational 2 weeks” from the retrieval date and “gestational 2 weeks 5 days” at the moment of a Day 5 transfer. The convention exists to ensure that IVF pregnancies are described in the same gestational age language as naturally conceived pregnancies, allowing direct comparison of fetal development, screening test timing, and prenatal milestones. Practically, an IVF patient who has a positive beta at 9dp5dt is approximately 3 weeks 6 days gestational age at that point (the embryo is 14 days post-fertilization, which equals 14 + 14 = 28 days from implied LMP, or 4 weeks gestational age), and the first heartbeat ultrasound scheduled at “6 to 7 weeks gestational age” is typically 6 to 7 weeks from the implied LMP, not from the transfer date. IVF patients sometimes calculate their gestational age from the transfer date and find it does not match what their RE or OB reports, which is confusing but reflects this systematic convention difference.

Preimplantation genetic testing (PGT) is a group of genetic screening technologies applied to embryos created through IVF before transfer to identify chromosomally normal (euploid) embryos, reducing the risk of chromosomal abnormalities in transferred pregnancies. The main types are: PGT-A (for aneuploidy, previously called PGS), which screens for the correct number of chromosomes; PGT-M (for monogenic disorders), which screens for specific inherited single-gene conditions; and PGT-SR (for structural rearrangements), which screens for embryos affected by chromosomal structural abnormalities in one or both parents. PGT testing requires a trophectoderm biopsy of the embryo, which can only be performed on blastocysts (Day 5 or Day 6 embryos), and the biopsy results require laboratory analysis (typically 7 to 14 days), meaning PGT cycles are virtually always frozen embryo transfer cycles. The embryos are biopsied, frozen, results are received while they are frozen, and only chromosomally normal embryos are thawed and transferred. PGT testing does not affect the due date calculation: the same formulas apply regardless of whether a Day 5 transfer embryo underwent PGT or not, since what matters for the calculation is the embryo’s developmental age at transfer (Day 5 in both cases). Current estimates suggest that PGT-A testing is performed in approximately 30 to 40% of IVF cycles in the US, with higher uptake among patients over 35 and those with recurrent pregnancy loss. The CDC collects IVF outcome data at cdc.gov/art and SART at sartcorsonline.com provides outcome statistics that allow comparison of PGT and non-PGT cycle outcomes at US fertility clinics.

The two-week wait (TWW), commonly discussed in IVF community forums, refers to the period between embryo transfer and the first beta hCG blood test, during which the patient waits to learn whether the transfer resulted in a pregnancy. Despite its name, the TWW is not actually two full weeks for most modern IVF protocols: for Day 5 transfers, the first beta is typically at 9dp5dt (9 days after a Day 5 transfer), which is only 9 days of waiting rather than 14. For Day 3 transfers, the first beta is at 11dp3dt (11 days), slightly longer but still under two weeks. The term “two-week wait” reflects the historical experience from early IVF protocols and from natural conception timing (where a pregnancy test is typically done approximately two weeks after ovulation or conception). During the TWW, patients are advised to continue all prescribed medications (progesterone supplementation and estrogen if indicated), avoid strenuous activity in the first few days post-transfer, maintain hydration, and avoid heat exposure such as hot tubs and saunas. At-home pregnancy tests (urine hCG tests) during the TWW are a source of significant anxiety: testing too early can produce false negatives (hCG not yet at detectable levels), and testing too early in cycles that used an hCG trigger shot can produce false positives from the residual trigger. The beta hCG blood test, which detects lower hCG concentrations than urine tests and produces a quantitative result, remains the clinical standard for pregnancy confirmation after IVF transfer. Many IVF clinics advise against home testing before the scheduled beta date, though most patients acknowledge that many people test at home regardless.

IVF due dates, once calculated from the transfer date using the standard formulas in this calculator, are typically very accurate and are rarely changed by subsequent ultrasound findings, unlike LMP-based due dates in naturally conceived pregnancies that are frequently adjusted at the first trimester ultrasound. This stability occurs because the IVF formula is already based on the exact fertilization date rather than an estimated ovulation date, removing the primary source of error in LMP dating. When an IVF patient transfers care to an OB-GYN at 8 to 10 weeks, the OB will confirm the due date using the crown-rump length (CRL) measurement on the first trimester ultrasound. If the CRL-based due date agrees with the transfer-calculated date within 7 days (the standard ACOG threshold for first trimester redating), the original IVF-calculated date is maintained. If there is a discrepancy greater than 7 days in the first trimester, the ultrasound date would take precedence per ACOG guidelines; however, this situation is unusual for IVF pregnancies because the starting gestational age is already precisely known. IVF patients transitioning to OB care should bring documentation of their transfer date and embryo type (Day 3 or Day 5) to the first OB appointment to facilitate accurate dating confirmation. The ACOG Committee Opinion on methods of estimating due date (ACOG CO-700) specifies that for IVF pregnancies, the embryo transfer date is the definitive reference for gestational age, and the implied LMP should be documented to ensure consistent dating throughout the pregnancy.

IVF pregnancies follow the same standard US prenatal screening schedule as naturally conceived pregnancies for most tests, including NIPT (10-13 weeks), nuchal translucency ultrasound (11-14 weeks), anatomy scan (18-22 weeks), glucose challenge test (24-28 weeks), and Group B Strep screening (36-37 weeks). However, several aspects of prenatal care differ for IVF pregnancies: because many IVF patients have already undergone PGT-A (preimplantation genetic testing for aneuploidy) before transfer and know their embryo was chromosomally normal, some patients and providers discuss whether first trimester chromosomal screening (NIPT/nuchal translucency) provides additional value beyond what PGT-A already determined. However, NIPT also screens for some microdeletions not covered by standard PGT-A panels, and the nuchal translucency ultrasound provides additional structural assessment beyond chromosomal analysis, so most providers continue to offer both for comprehensive first trimester evaluation even after PGT-A. IVF pregnancies, particularly those involving older maternal age (the most common indication for IVF) and multifetal pregnancies, are generally classified as higher-risk and may be managed by maternal-fetal medicine specialists rather than general OB-GYNs for portions of the prenatal course. Twin pregnancies resulting from IVF (which occur when two embryos are transferred or when a single embryo splits into identical twins) require more intensive monitoring than singleton pregnancies, with additional ultrasounds to assess twin-to-twin transfusion risk and cervical length. Current ASRM guidelines recommend single embryo transfer (SET) for most patients under 38 to reduce multiple pregnancy risk, with SET now the standard of care at most US fertility clinics per asrm.org.

A standard IVF cycle in the United States involves several phases that occur before the embryo transfer and due date calculation: ovarian stimulation (approximately 8 to 14 days) involves daily self-injection of gonadotropin medications (FSH and sometimes LH) to stimulate the ovaries to produce multiple follicles containing mature eggs, with monitoring via vaginal ultrasounds and blood estradiol levels typically every 1 to 3 days; oocyte trigger and retrieval involves a final injection of hCG or a GnRH agonist trigger shot approximately 36 hours before the egg retrieval procedure, which is typically a 15 to 30 minute outpatient procedure under intravenous sedation; fertilization occurs on the day of retrieval when retrieved eggs are inseminated with prepared sperm (either via conventional insemination or intracytoplasmic sperm injection or ICSI), with fertilization confirmed the following morning; embryo culture for 3 to 6 days in the embryology laboratory to blastocyst stage in a majority of modern US IVF programs; and finally, transfer or freeze (all-freeze strategy). The entire cycle from stimulation start to either fresh transfer or freeze-all takes approximately 3 to 5 weeks. For frozen transfers following a freeze-all strategy, a separate FET cycle is prepared over approximately 2 to 4 weeks using estrogen and progesterone to prepare the uterine lining. Total time from starting stimulation to a positive pregnancy test in a fresh cycle is typically 5 to 7 weeks. The CDC’s ART surveillance report at cdc.gov/art and the ASRM patient resources at asrm.org provide comprehensive information on IVF procedures, success rates, and what to expect throughout the process for US patients.

This IVF due date calculator is specifically designed for pregnancies achieved through in vitro fertilization and uses embryo-age-specific formulas (transfer date plus 261 for Day 5, transfer date plus 263 for Day 3) that are more accurate for IVF patients than the LMP-based Naegele’s Rule used in the standard pregnancy due date calculator. The key differences: this calculator accepts the embryo transfer date or egg retrieval date as the primary input, whereas the standard calculator uses last menstrual period or conception date; this calculator distinguishes between Day 3, Day 5, and Day 6 transfer embryos and calculates the EDD differently for each; this calculator generates IVF-specific beta hCG test dates (9dp5dt, 11dp5dt for Day 5; 11dp3dt for Day 3) that are not relevant to naturally conceived pregnancies; and this calculator includes the RE graduation milestone date, which is specific to IVF care coordination. The milestone calendar in this calculator includes IVF-specific early monitoring appointments (beta 1, beta 2, heartbeat confirmation, RE graduation) before the standard OB prenatal milestones begin, reflecting the more intensive early monitoring that IVF pregnancies receive compared to naturally conceived pregnancies. For pregnancies conceived through IUI (intrauterine insemination) or naturally with known conception dates, the standard pregnancy due date calculator is more appropriate, as the IUI/natural conception calculator uses the conception date plus 266 days formula, which is also available on this site at the Pregnancy Due Date Calculator page.

The number of embryos transferred does not change the due date calculation: whether one or two embryos are transferred on Day 5, the EDD is still calculated as transfer date plus 261 days. However, if two embryos are transferred and both implant, the resulting twin pregnancy may have a different clinical management approach and different likelihood of preterm birth that makes the nominal EDD (40 weeks) less clinically relevant than for singleton pregnancies. Twins in the US have a median gestational age at delivery of approximately 35 to 37 weeks for dichorionic-diamniotic (DC-DA) twins and 34 to 36 weeks for monochorionic-diamniotic (MC-DA) twins, meaning the probability of reaching the 40-week EDD is substantially lower than for singleton pregnancies. For twin pregnancies, OB and MFM (maternal-fetal medicine) providers typically plan delivery at 38 weeks for DC-DA twins and 36 to 37 weeks for MC-DA twins, making the 40-week EDD a theoretical rather than target date in most twin pregnancies. The American Society for Reproductive Medicine (ASRM) and Society for Assisted Reproductive Technology (SART) strongly recommend single embryo transfer (SET) for most IVF patients under 38 with good prognosis, citing the significantly higher rate of preterm birth, low birth weight, NICU admission, and maternal complications associated with twin pregnancies conceived through IVF. Current SART data shows that the proportion of IVF cycles using SET has increased substantially over the past decade and now represents the majority of transfers in patients under 40 at most US IVF centers.

Several major US organizations provide authoritative resources and support for patients undergoing IVF and other assisted reproductive technologies. The American Society for Reproductive Medicine (ASRM) at asrm.org is the premier professional organization for US fertility specialists and publishes evidence-based practice guidelines, patient education materials on all aspects of IVF, and information on fertility treatment options for various diagnoses. The Society for Assisted Reproductive Technology (SART) at sartcorsonline.com publishes annual US IVF success rate data by clinic, allowing prospective patients to compare success rates at US fertility centers using standardized methodology. The Centers for Disease Control and Prevention (CDC) at cdc.gov/art publishes comprehensive national ART surveillance data annually, including success rates by patient age, diagnosis, and treatment type. The Resolve: The National Infertility Association at resolve.org provides peer support, advocacy, and patient education resources specifically for people experiencing infertility, including fertility preservation information and resources for IVF financial assistance programs. For IVF insurance coverage: as of 2024, 20 US states have enacted some form of fertility treatment insurance mandate, with coverage varying significantly by state and plan type. The National Infertility Association maintains an insurance coverage guide at resolve.org that tracks state-by-state IVF insurance mandates and helps patients understand their coverage. The cost of a single IVF cycle in the US without insurance averages between $12,000 and $20,000 per cycle including medications, with significant variation by geographic market and clinic, making the insurance and financial resources available through Resolve particularly valuable for patients navigating IVF costs.

Ovarian hyperstimulation syndrome (OHSS) is a medical complication of IVF that occurs when the ovaries over-respond to fertility medications, producing a large number of follicles and releasing hormones and fluid into the body. Symptoms range from mild (bloating, pelvic discomfort, mild nausea) to severe (significant abdominal distension, difficulty breathing from fluid accumulation in the abdomen and chest, blood clotting risk, and in rare cases kidney or liver dysfunction requiring hospitalization). OHSS is more common in women who are young, have polycystic ovary syndrome (PCOS), have a high antral follicle count, or have high estradiol levels during stimulation. In IVF practice, OHSS significantly influences transfer strategy: women who develop significant OHSS during a fresh cycle are typically managed with a freeze-all approach, freezing all embryos and postponing transfer to a subsequent cycle when OHSS has fully resolved. This is because pregnancy markedly worsens OHSS due to hCG production from a newly implanted embryo, potentially turning moderate OHSS into severe OHSS. The freeze-all strategy for OHSS prevention does not affect the eventual due date calculation: when transfer occurs in the subsequent FET cycle, the standard formulas (transfer date plus 261 for Day 5) apply. The risk of OHSS has been substantially reduced in modern IVF practice through the use of GnRH agonist trigger shots (instead of hCG trigger) in high-risk patients, lower gonadotropin stimulation protocols, and aggressive freeze-all policies. Detailed OHSS prevention and management guidelines are available from ASRM at asrm.org and the American College of Obstetricians and Gynecologists at acog.org.

IVF success rates in the United States vary substantially by patient age, reflecting the age-related decline in egg quality (chromosomal integrity) that is the primary limiting factor for fertility treatment. The most current national data, published by the CDC’s ART surveillance program at cdc.gov/art and SART at sartcorsonline.com, shows live birth rates per intended egg retrieval cycle using own eggs of approximately: 40 to 50% per cycle for patients under 35; 30 to 40% for patients aged 35 to 37; 20 to 30% for patients aged 38 to 40; 10 to 20% for patients aged 41 to 42; and 5 to 10% for patients above 43. For frozen embryo transfers (FET), success rates per transfer are somewhat higher than per-retrieval rates because the transfer step only occurs if at least one viable embryo was frozen, removing cycles with no embryos to transfer from the denominator. It is important to understand that these are national averages and individual clinic rates vary significantly based on patient selection, laboratory quality, and treatment protocols. Patients using donor eggs (eggs from a younger donor) have substantially higher success rates (typically 45 to 55% per transfer) regardless of the recipient’s age, because success is primarily determined by egg age rather than uterine age for most patients. Patients who have undergone PGT-A (genetic testing of embryos) and are transferring a single confirmed euploid (chromosomally normal) embryo have higher success rates per transfer (approximately 60 to 70%) than unscreened single embryo transfers, though PGT-A requires successful blastocyst formation and biopsy that not all cycles achieve.

Progesterone supplementation after IVF embryo transfer is standard of care in the US because IVF cycles disrupt the normal luteal phase (post-ovulation hormonal support for the uterine lining) in a way that requires exogenous progesterone to support implantation and early pregnancy maintenance. The corpus luteum (the structure in the ovary that produces progesterone after ovulation in natural cycles) is disrupted by the egg retrieval process in IVF, reducing natural progesterone output below the levels needed to support early pregnancy. Progesterone support is given in several forms: vaginal progesterone suppositories or gel (Crinone, Endometrin), which are most commonly used in US IVF practice due to high local concentration in the uterus with lower systemic side effects; intramuscular progesterone in oil (PIO) injections, which are more commonly used for patients with prior implantation failure or for FET cycles using hormone-only (artificial) protocols; and in some cases subcutaneous progesterone injections (Prolutex) or oral progesterone (Prometrium). For fresh IVF cycles, progesterone support typically begins on the day of the egg retrieval and continues if pregnancy is confirmed. For frozen embryo transfers using hormone-supported (artificial) protocols, progesterone begins approximately 5 to 7 days before the transfer and continues after. Duration of progesterone support varies by clinic protocol, but most US fertility clinics taper and stop progesterone between 8 and 12 weeks of pregnancy (gestational age), when the placenta is producing sufficient progesterone to support the pregnancy independently. Stopping progesterone earlier than 8 weeks is associated with increased pregnancy loss risk in medically supported cycles. Your RE will provide a specific tapering schedule; never stop progesterone without consulting your RE, as abrupt discontinuation before placental progesterone production is established can threaten the pregnancy.